Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wittman

Showing results (271-280 of 286) with videos related to

Pageof 29
Sort By:
Nature Communications|August 1, 2020
Strategies to enable large-scale proteomics for reproducible researchRebecca C Poulos, Peter G Hains, Rohan Shah, et al.
Journal for Immunotherapy of Cancer|January 7, 2021
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitorDan You, Stephen Hillerman, Gregory Locke, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|August 19, 2020
Acute stroke care in a New York City comprehensive stroke center during the COVID-19 pandemicShashank Agarwal, Erica Scher, Nirmala Rossan-Raghunath, et al.
Journal of Medicinal Chemistry|September 2, 2005
Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activityMark Wittman, Joan Carboni, Ricardo Attar, et al.
Journal of Medicinal Chemistry|September 26, 2009
Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical developmentMark D Wittman, Joan M Carboni, Zheng Yang, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2021
Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19Dorien Feyaerts, Julien Hédou, Joshua Gillard, et al.
JCI Insight|July 8, 2022
Anti-nucleocapsid antibody levels and pulmonary comorbid conditions are linked to post-COVID-19 syndromeXiaolin Jia, Shu Cao, Alexandra S Lee, et al.
JAMA|January 15, 2025
Palliative Care Initiated in the Emergency Department: A Cluster Randomized Clinical TrialCorita R Grudzen, Nina Siman, Allison M Cuthel, et al.
Cell Reports. Medicine|July 15, 2022
Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19Dorien Feyaerts, Julien Hédou, Joshua Gillard, et al.
Nature Communications|September 15, 2021
New-onset IgG autoantibodies in hospitalized patients with COVID-19Sarah Esther Chang, Allan Feng, Wenzhao Meng, et al.
Pageof 29

Showing results (271-280 of 286) with videos related to

Sort By:
Pageof 29
Nature Communications|August 1, 2020
Strategies to enable large-scale proteomics for reproducible researchRebecca C Poulos, Peter G Hains, Rohan Shah, et al.
Journal for Immunotherapy of Cancer|January 7, 2021
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitorDan You, Stephen Hillerman, Gregory Locke, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|August 19, 2020
Acute stroke care in a New York City comprehensive stroke center during the COVID-19 pandemicShashank Agarwal, Erica Scher, Nirmala Rossan-Raghunath, et al.
Journal of Medicinal Chemistry|September 2, 2005
Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activityMark Wittman, Joan Carboni, Ricardo Attar, et al.
Journal of Medicinal Chemistry|September 26, 2009
Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical developmentMark D Wittman, Joan M Carboni, Zheng Yang, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2021
Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19Dorien Feyaerts, Julien Hédou, Joshua Gillard, et al.
JCI Insight|July 8, 2022
Anti-nucleocapsid antibody levels and pulmonary comorbid conditions are linked to post-COVID-19 syndromeXiaolin Jia, Shu Cao, Alexandra S Lee, et al.
JAMA|January 15, 2025
Palliative Care Initiated in the Emergency Department: A Cluster Randomized Clinical TrialCorita R Grudzen, Nina Siman, Allison M Cuthel, et al.
Cell Reports. Medicine|July 15, 2022
Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19Dorien Feyaerts, Julien Hédou, Joshua Gillard, et al.
Nature Communications|September 15, 2021
New-onset IgG autoantibodies in hospitalized patients with COVID-19Sarah Esther Chang, Allan Feng, Wenzhao Meng, et al.
Pageof 29